Technical Analysis for TRVN - Trevena, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -2.04% | |
| Narrow Range Bar | Range Contraction | -2.04% | |
| Wide Bands | Range Expansion | -2.04% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 21 hours ago |
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
| Rose Above Previous Day's High | 2 days ago |
| 10 DMA Resistance | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
Trevena, Inc. Description
Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the µ-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Organic Compounds Opioids Chronic Pain Heart Failure Central Nervous System Disorders Signal Transduction Analgesics Nervous System Disorders Acute Pain Pyridines Cell Signaling Acute And Chronic Pain Treatment Of Central Nervous System Disorders Opioid Receptors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.2325 |
| 52 Week Low | 1.13 |
| Average Volume | 42,838 |
| 200-Day Moving Average | 8.54 |
| 50-Day Moving Average | 3.54 |
| 20-Day Moving Average | 1.99 |
| 10-Day Moving Average | 1.76 |
| Average True Range | 0.50 |
| RSI (14) | 38.27 |
| ADX | 19.85 |
| +DI | 19.81 |
| -DI | 23.00 |
| Chandelier Exit (Long, 3 ATRs) | 3.17 |
| Chandelier Exit (Short, 3 ATRs) | 2.64 |
| Upper Bollinger Bands | 3.29 |
| Lower Bollinger Band | 0.70 |
| Percent B (%b) | 0.38 |
| BandWidth | 130.15 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.63 |
| MACD Histogram | 0.0735 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.13 | ||||
| Resistance 3 (R3) | 2.18 | 2.08 | 2.06 | ||
| Resistance 2 (R2) | 2.08 | 1.97 | 2.06 | 2.03 | |
| Resistance 1 (R1) | 1.88 | 1.89 | 1.83 | 1.83 | 2.00 |
| Pivot Point | 1.78 | 1.78 | 1.76 | 1.76 | 1.78 |
| Support 1 (S1) | 1.58 | 1.67 | 1.53 | 1.53 | 1.36 |
| Support 2 (S2) | 1.48 | 1.59 | 1.46 | 1.33 | |
| Support 3 (S3) | 1.28 | 1.48 | 1.31 | ||
| Support 4 (S4) | 1.23 |
